Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > Chuikyo Debate on FY2026 Drug Pricing Reform
Chuikyo Debate on FY2026 Drug Pricing Reform
-
Deeper CEA Price Cuts Mooted for “Cost Increase” Products: FY2026 Reform Debate
October 16, 2025
-
Chuikyo Urges Stricter Pricing Rules for Conditionally Approved Regenerative Medicines
October 16, 2025
-
Chuikyo Frowns on Industry Calls for Scrapping Huge-Seller Re-Pricing, Spillovers
October 9, 2025
-
Chuikyo Wary of Revising “Zero” Premium Rule for Low Cost Disclosure
October 9, 2025
-
Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
-
Pharmacies, Wholesalers Split on Weekend Deliveries at Chuikyo
September 18, 2025
-
Generic Firms Push Reform to Ensure Stability, Wholesalers Seek End to Off-Year Cuts
September 18, 2025
-
FIRM Calls for Pricing Overhaul to Reflect Unique Benefits of Regenerative Therapies
September 18, 2025
-
FPMAJ Urges Blanket Drug Price Hikes to Offset Inflation: FY2026 Reform Talks
September 18, 2025
-
Tensions Flare at Chuikyo over Premiums for Generic Dispensing
September 16, 2025
-
Japan to Discuss Negative Margins, Packaging Optimization towards FY2026 Reform
August 8, 2025
-
Medical Device Pricing Body Urges Clearer Evaluation Criteria for SaMDs Reimbursement
August 8, 2025
-
Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
August 7, 2025
-
DPO Floats Premium Expansion, Relaxed Criteria towards FY2026 Reform
August 7, 2025
-
Japan Begins FY2026 CEA Reform Talks, Re-Designation after Market Expansion Up for Debate
July 17, 2025
-
Generic and Wholesaler Groups Call for Pricing Reforms to Reflect Inflationary Pressures
July 11, 2025
-
16 Drugs Enter Japan Trials after Pro-Innovation Reform: Industry Poll
July 10, 2025
-
Pharma Groups Renew Push for Price Stability During Patent Term as FY2026 Reform Talks Begin
July 10, 2025
-
Trade Groups Urge Pricing Overhaul for Regenerative Medicines, Biotech Drugs
July 10, 2025
-
Japan Begins FY2026 Drug Pricing Reform Talks; Responses to Inflation, High-Cost Therapies on Agenda
June 26, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…